Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Pravastatin sodium [USAN:USP:JAN]
RN: 81131-70-6
UNII: 3M8608UQ61
InChIKey: VWBQYTRBTXKKOG-IYNICTALSA-M

Note

  • An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).

Molecular Formula

  • C23-H35-Na-O7

Molecular Weight

  • 446.5125
 

Classification Codes

  • Antihyperlipidemic
  • Drug / Therapeutic Agent
  • Human Data
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Pravastatin sodium [USAN:USP:JAN]

Synonyms

  • 3-beta-Hydroxycompactin sodium salt
  • Aplactin
  • Bristacol
  • CS-514
  • DRG-0319
  • Elisor
  • Epastatin sodium
  • Lipemol
  • Lipidal
  • Lipostat
  • Liprevil
  • Mevalotin
  • Pralidon
  • Prareduct
  • Pravachol
  • Pravacol
  • Pravaselect
  • Pravasin
  • Pravasine
  • Pravastatin Natrium Mayrho Fer
  • Pravastatin sodium
  • Sanaprav
  • Selektine
  • Selipran
  • Sodium (+)-(betaR,deltaR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-hexahydro-beta,delta,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-((2S)-2-methylbutyrate)
  • SQ 31000
  • SQ-31,000
  • UNII-3M8608UQ61
  • Vasen

Systematic Names

  • 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-2-methyl-8-(2-methyl-1-oxobutoxy)-beta,delta,6-trihydroxy-, monosodium salt, (1S-(1-alpha(beta-S*,delta-S*),2-alpha,6-alpha,8-beta(R*),8a-alpha))-
  • 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, (1S-(1alpha(betaS*,deltaS*),2alpha,6alpha,8beta(R*),8aalpha))-

Superlist Name

  • Pravastatin sodium

Mixture Name

  • Pravigard PAC

Registry Numbers

CAS Registry Number

  • 81131-70-6

FDA UNII

  • 3M8608UQ61

Other Registry Numbers

  • 115873-26-2
  • 81131-73-9
  • 85956-24-7
  • 87098-76-8

Related Registry Number

  • 81093-37-0 (Parent)

System Generated Number

  • 0081131706

Structure Descriptors

InChI

InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

InChIKey

VWBQYTRBTXKKOG-IYNICTALSA-M

Smiles

[Na+].CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@@H]12

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo oral 16mg/kg/8W-I (16mg/kg) LIVER: "JAUNDICE, CHOLESTATIC"

LIVER: LIVER FUNCTION TESTS IMPAIRED

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"
American Journal of Emergency Medicine. Vol. 17, Pg. 1388, 1999.
mouse LD50 intravenous 2011mg/kg (2011mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987.
mouse LD50 oral 8939mg/kg (8939mg/kg) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"

SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE

BLOOD: CHANGES IN SPLEEN
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987.
mouse LD50 subcutaneous 2975mg/kg (2975mg/kg) SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987.
rat LD50 intravenous 440mg/kg (440mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987.
rat LD50 oral > 12gm/kg (12000mg/kg)   Yakkyoku. Pharmacy. Vol. 40, Pg. 2351, 1989.
rat LD50 subcutaneous 3172mg/kg (3172mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

BEHAVIORAL: ATAXIA

SKIN AND APPENDAGES (SKIN): HAIR: OTHER
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987.
rat LDLo intraperitoneal 400mg/kg (400mg/kg)   Biochemistry and Molecular Biology International. Vol. 47, Pg. 519, 1999.
women TDLo oral 16800ug/kg (16.8mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) Lancet. Vol. 340, Pg. 910, 1992.
women TDLo oral 30mg/kg/21W-I (30mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"

BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"

BEHAVIORAL: MUSCLE WEAKNESS
New England Journal of Medicine. Vol. 327, Pg. 649, 1992.

Physical Properties

Physical Property Value Units Temp (deg C) Source
log P (octanol-water) -0.23 (none)   EXP
Water Solubility 2460 mg/L 25 EST
Vapor Pressure 3.60E-23 mm Hg 25 EST
Atmospheric OH Rate Constant 2.41E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.